Altered Expression of Signalling Lymphocyte Activation Molecule Receptors in T-cells from Lupus Nephritis Patients-a Potential Biomarker of Disease Activity

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2017 Apr 8

PMID 28387859

Citations 7

Authors

Victoria Stratigou

Anne F Doyle

Francesco Carlucci

Lauren Stephens

Valentina Foschi

Marco Castelli

Nicola McKenna

H Terence Cook

Liz Lightstone

Thomas D Cairns

Matthew C Pickering

Marina Botto

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim was to investigate whether the signalling lymphocyte activation molecule (SLAM) signalling pathways contribute to LN and whether SLAM receptors could be valuable biomarkers of disease activity.

Methods: Peripheral blood mononuclear cells from 30National Research Ethics Service SLE patients with biopsy-proven LN were analysed by flow cytometry. Clinical measures of disease activity were assessed. The expression of the SLAM family receptors on T-cell subpopulations [CD4, CD8 and double negative (DN) T cells] was measured and compared between lupus patients with active renal disease and those in remission.

Results: The frequency of CD8 T cells expressing SLAMF3, SLAMF5 and SLAMF7 was significantly lower in LN patients who were in remission. In contrast, these subsets were similar in patients with active renal disease and in healthy individuals. Patients with active nephritis had an increased percentage of circulating monocytes, consistent with a potential role played by these cells in glomerular inflammation. Changes in the frequency of DN T cells positive for SLAMF2, SLAMF4 and SLAMF7 were observed in lupus patients irrespective of the disease activity. We detected alterations in the cellular expression of the SLAM family receptors, but these changes were less obvious and did not reveal any specific pattern. The percentage of DN T cells expressing SLAMF6 could predict the clinical response to B-cell depletion in patients with LN.

Conclusion: Our study demonstrates altered expression of the SLAM family receptors in SLE T lymphocytes. This is consistent with the importance of the SLAM-associated pathways in lupus pathogenesis.

Citing Articles

Double-Negative T (DNT) Cells in Patients with Systemic Lupus Erythematosus.

Poddighe D, Dossybayeva K, Kozhakhmetov S, Rozenson R, Assylbekova M Biomedicines. 2024; 12(1).

PMID: 38255272 PMC: 10812956. DOI: 10.3390/biomedicines12010166.

Molecular mechanisms governing the progression of nephritis in lupus prone mice and human lupus patients.

Daamen A, Wang H, Bachali P, Shen N, Kingsmore K, Robl R Front Immunol. 2023; 14:1147526.

PMID: 36936908 PMC: 10016352. DOI: 10.3389/fimmu.2023.1147526.

SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus.

Humbel M, Bellanger F, Horisberger A, Suffiotti M, Fluder N, Makhmutova M Front Immunol. 2022; 13:843059.

PMID: 35603218 PMC: 9120573. DOI: 10.3389/fimmu.2022.843059.

Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus.

Wincup C, Sawford N, Rahman A Expert Rev Clin Immunol. 2021; 17(9):957-967.

PMID: 34263712 PMC: 8452144. DOI: 10.1080/1744666X.2021.1953981.

SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity.

Gartshteyn Y, Askanase A, Mor A Front Immunol. 2021; 12:654839.

PMID: 33936082 PMC: 8086963. DOI: 10.3389/fimmu.2021.654839.

References

Hagberg N, Theorell J, Schlums H, Eloranta M, Bryceson Y, Ronnblom L . Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells. J Immunol. 2013; 191(6):2989-98. DOI: 10.4049/jimmunol.1301022. View

Vital E, Dass S, Buch M, Henshaw K, Pease C, Martin M . B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011; 63(10):3038-47. DOI: 10.1002/art.30466. View

Chan A, Westcott J, Mooney J, Wakeland E, Schatzle J . The role of SAP and the SLAM family in autoimmunity. Curr Opin Immunol. 2006; 18(6):656-64. DOI: 10.1016/j.coi.2006.09.010. View

Ramos-Casals M, Soto M, Cuadrado M, Khamashta M . Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009; 18(9):767-76. DOI: 10.1177/0961203309106174. View

Erard F, Wild M, Garcia-Sanz J, Le Gros G . Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells. Science. 1993; 260(5115):1802-5. DOI: 10.1126/science.8511588. View

Dorner T, Jacobi A, Lee J, Lipsky P . Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2010; 363(2):187-97. DOI: 10.1016/j.jim.2010.06.009. View

Moroni G, Pasquali S, Quaglini S, Banfi G, Casanova S, Maccario M . Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis. 1999; 34(3):530-9. DOI: 10.1016/s0272-6386(99)70082-x. View

Keszei M, Detre C, Rietdijk S, Munoz P, Romero X, Berger S . A novel isoform of the Ly108 gene ameliorates murine lupus. J Exp Med. 2011; 208(4):811-22. PMC: 3135348. DOI: 10.1084/jem.20101653. View

Kis-Toth K, Comte D, Karampetsou M, Kyttaris V, Kannan L, Terhorst C . Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015; 68(1):164-73. PMC: 4690788. DOI: 10.1002/art.39410. View

10.

Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P . Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum. 2011; 63(6):1698-706. DOI: 10.1002/art.30313. View

11.

McKinney E, Lyons P, Carr E, Hollis J, Jayne D, C Willcocks L . A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010; 16(5):586-91, 1p following 591. PMC: 3504359. DOI: 10.1038/nm.2130. View

12.

Wandstrat A, Nguyen C, Limaye N, Chan A, Subramanian S, Tian X . Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity. 2004; 21(6):769-80. DOI: 10.1016/j.immuni.2004.10.009. View

13.

Jacobi A, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A . Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 2008; 58(6):1762-73. DOI: 10.1002/art.23498. View

14.

Wu N, Veillette A . SLAM family receptors in normal immunity and immune pathologies. Curr Opin Immunol. 2015; 38:45-51. DOI: 10.1016/j.coi.2015.11.003. View

15.

Merrill J, Neuwelt C, Wallace D, Shanahan J, Latinis K, Oates J . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2009; 62(1):222-33. PMC: 4548300. DOI: 10.1002/art.27233. View

16.

Lydyard P, Isenberg D . Lack of NK cells in lupus patients with renal involvement. Lupus. 1997; 6(9):708-12. DOI: 10.1177/096120339700600905. View

17.

Furukawa H, Tohma S, Kitazawa H, Komori H, Nose M, Ono M . Role of SLAM-associated protein in the pathogenesis of autoimmune diseases and immunological disorders. Arch Immunol Ther Exp (Warsz). 2010; 58(1):37-44. DOI: 10.1007/s00005-009-0060-7. View

18.

Condon M, Ashby D, Pepper R, Cook H, Levy J, Griffith M . Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013; 72(8):1280-6. DOI: 10.1136/annrheumdis-2012-202844. View

19.

Schleinitz N, Vely F, Harle J, Vivier E . Natural killer cells in human autoimmune diseases. Immunology. 2010; 131(4):451-8. PMC: 2999796. DOI: 10.1111/j.1365-2567.2010.03360.x. View

20.

Lazarus M, Turner-Stokes T, Chavele K, Isenberg D, Ehrenstein M . B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford). 2012; 51(7):1208-15. PMC: 3380246. DOI: 10.1093/rheumatology/ker526. View